“We’re excited to hear from our clinics that the protonotherapy therapy can help this vantagon, but we’re not convinced that the fosse effect should be considered,” said James Metz, MD, President of Radiation Oncology, President of the Roberts Proton Therapy Center press Penn and CEO of Penn’s Abramson Cancer Center.
“Sappiamo dalla nostra esperienza clinica che la terapia protonica pu avere questo vantaggio, ma non ci aspettavamo che l’effetto fosse cos considerevole”, ha affermato l’autore senior James Metz, MD, Presidente di Radiation Oncology, leader del Roberts Proton Therapy Center presso Penn e membro del Penn’s Abramson Cancer Center.